Daewon Pharmaceutical announced on the 24th that it has signed a joint promotion contract between Boryeong Pharmaceutical and Kanab Family (Akab, Tubero), a new drug for treating hypertension.
At the signing ceremony of the joint promotion contract held at the headquarters of Daewon Pharmaceutical on the 23rd, Daewon Pharmaceutical Vice Chairman Seung-yeol Baek, President Tae-hong Choi, and CEO Ahn Jae-hyun and Lee Sam-soo of Boryeong Pharmaceutical attended.
The two products that will be jointly sold are’Akab’ and’Tubero’, a combination drug of’Kannab’, an existing high blood pressure treatment, plus a treatment for hyperlipidemia, among Boryeong Pharmaceutical’s representative blockbuster new drug’Kannab’ family.
‘Tubero’ is a product that improves the patient’s medication convenience by combining’Pimasartan’, an ingredient of Kanab, a new hypertension drug, and’Rosuvastatin’, a treatment ingredient for hyperlipidemia, and was launched in 2016.’Akab’ is Kanab’s It is a new product released this year as a combination of the ingredient’pimasartan’ and’atorvastatin’, which is used as a treatment for hyperlipidemia.
With this contract, the distribution, sales and marketing of’Tubero’ to all domestic hospitals and clinics will be handled by Daewon Pharmaceutical, and the distribution of’Akave’ will be conducted by Daewon Pharmaceutical, and sales and marketing will be jointly conducted by both companies.
Jae-Hyun Ahn, CEO of Boryeong Pharmaceutical said, “The Kanab Family is recognized for its marketability at home and abroad through its excellent clinical value as a successful model for domestic new drugs.” We look forward to helping more patients improve their quality of life.
Daewon Pharm’s Vice Chairman Seung-Yeol Baek said, “Based on Daewon Pharm’s differentiated marketing capabilities and sales know-how, we strive to expand the market share of the’Kannab’ brand so that more hypertension and hyperlipidemia patients can benefit from the treatment benefits of the innovative new drug Kanab Family. “We will continue to expand our product portfolio in the area of chronic diseases in the future so that we can contribute to the improvement of public health,” he said.